AnGes is headquartered in Ibaraki, Japan.
AnGes disclosed revenue of 644M JPY for 2024 and 153M JPY for 2023.
AnGes has 55 employees.
AnGes is a life science company.
AnGes was founded in 1999.
Saito Bio-Incubator, 1st Floor 7-7-15, Saito-asagi,
Ibaraki,
567-0085
Japan,
www.anges.co.jp
AnGes is a biopharmaceutical company that focuses on the development of gene‐based medicines. AnGes obtained conditional and time‐limited approval for its lead product, Collategene (Hepatocyte Growth Factor, HGF, plasmid gene therapy), for the treatment of Lower Limb Ischemic Ulcers. In September 2019, AnGes commenced the commercialization in Japan of Collategene . Collategene is the world’s first marketed drug using Plasmid DNA. AnGes was founded in 1999 and is based in Ibaraki, Japan.
| Year | ≤ '20 | '21 | '22 | '23 | '24 | '25 | T | |
|---|---|---|---|---|---|---|---|---|
| Buy (0.0/yr) | # | 1 | - | - | - | - | - | 1 |
| vol | $250M | $250M | ||||||
| Sell (0.0/yr) | # | - | - | - | - | - | - | 0 |
| 1 | ||||||||
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
